UK Markets closed

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.7800+0.0800 (+11.43%)
At close: 03:50PM EDT
0.8000 +0.02 (+2.56%)
After hours: 05:55PM EDT

AgeX Therapeutics, Inc.

1101 Marina Village Parkway
Suite 201
Alameda, CA 94501
United States
510 671 8370
https://www.agexinc.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees5

Key executives

NameTitlePayExercisedYear born
Dr. Michael D. West Ph.D.Founder, Pres, CEO & Director561.28kN/A1953
Ms. Eun-Jae Park CPAChief Financial Officer279.32kN/A1972
Dr. Nafees Naseer Malik M.D.Chief Operating Officer282.27kN/A1977
Dr. Ivan LabatChief Information OfficerN/AN/AN/A
Ms. Judith SegallSec.N/AN/A1953
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Corporate governance

AgeX Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.